Slowing sales, mega-mergers, generic implosions and whipsawing exchange rates have caused some shakeups within the Top 20 Pharma ranks. The loss of Wyeth and Schering-Plough, coupled with Roche’s defection to the Biopharma list, led us to find several new players: Otsuka, Gilead and Mylan.
I’m not sure how significant it is that half of “the second tier” (companies 11-20) are based in Japan, but I find it interesting that Gilead (#19) is the only non-generic U.S. pharma company in that tier. (Just below the cutoff line, companies #21 and #22 are Dutch and Japanese, respectively.) I also find it interesting that Teva has revenue goals that could propel it into the top 7 ranks in the next few years. Aim high, pharma!
—Gil Y. Roth, Editor
| Top 20 Pharmaceutical Companies |
| 01 |
Pfizer |
$45,448 |
| 02 |
Sanofi-Aventis |
$40,871 |
| 03 |
Novartis |
$38,455 |
| 04 |
GlaxoSmithKline |
$36,746 |
| 05 |
AstraZeneca |
$31,905 |
| 06 |
Merck & Co. |
$26,929 |
| 07 |
Johnson & Johnson |
$22,520 |
| 08 |
Eli Lilly & Co. |
$20,629 |
| 09 |
Bristol-Myers Squibb |
$18,808 |
| 10 |
Abbott Laboratories |
$16,486 |
| 11 |
Takeda Chem. Ind. |
$14,204 |
| 12 |
Boehringer-Ingelheim |
$14,027 |
| 13 |
Teva Pharma |
$13,814 |
| 14 |
Bayer Schering |
$13,344 |
| 15 |
Astellas |
$10,509 |
| 16 |
Daiichi-Sankyo |
$9,757 |
| 17 |
Eisai |
$8,441 |
| 18 |
Otsuka |
$9,646 |
| 19 |
Gilead Sciences |
$7,900 |
| 20 |
Mylan |
$7,612 |
Source :
http://www.contractpharma.com